MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate

Jiang,Liangdong; He,Aiyong; He,Xiaojie; Tao,Cheng

doi:10.3892/ol.2015.3790

MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate

Authors:
- Liangdong Jiang
- Aiyong He
- Xiaojie He
- Cheng Tao
View Affiliations

Affiliations: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: October 9, 2015 https://doi.org/10.3892/ol.2015.3790
Pages: 3769-3778

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The establishment of novel chemotherapy drugs for osteosarcoma is urgently required, and the mechanisms and effects of cisplatin (DDP) and methotrexate (MTX) in the current treatment of osteosarcoma have not been fully elucidated. The present study aimed to observe the effect of DDP, MTX and rapamycin on osteosarcoma cell proliferation and apoptosis, and to investigate the association between miR‑126 and the effects of DDP and MTX in osteosarcoma cells. miR‑126‑overexpressing and ‑silencing lentiviral vectors were constructed, and MG63 and U‑2 OS osteosarcoma cells were infected. An MTT assay was conducted to detect transfected cell proliferation, and the effects of the chemotherapy drugs on transfected cell apoptosis were detected by flow cytometry. The cell cycle of the transfected cells was analyzed via flow cytometry. As the miR‑126‑overexpressing and ‑silencing osteosarcoma cell lines were successfully constructed, it was observed that DDP and MTX inhibited osteosarcoma cell proliferation. With the decreased expression of miR‑126, the sensitivity of osteosarcoma cells to DDP and MTX was reduced at the same concentration. The flow cytometry suggested that DDP and MTX could promote the apoptosis of osteosarcoma cells with overexpressed miR‑126, whereas they could not significantly impact the apoptosis of the miR‑126‑silenced osteosarcoma cells. Meanwhile, DDP inhibited the cell cycle of the miR‑126‑overexpressing osteosarcoma cells. In conclusion, DDP and MTX inhibited the proliferation and promoted the apoptosis of the osteosarcoma cells, and these processes were dependent upon the expression of miR-126.

View Figures

View References

1	Chang SH and Hla T: Post-transcriptional gene regulation by HuR and microRNAs in angiogenesis. Curr Opin Hematol. 21:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
2	Kane NM, Howard L, Descamps B, Meloni M, McClure J, Lu R, McCahill A, Breen C, Mackenzie RM, Delles C, et al: Role of microRNAs 99b, 181a and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells. 30:643–654. 2012. View Article : Google Scholar : PubMed/NCBI
3	Mishra RR, Kneitz S and Schartl M: Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models. Comp Biochem Physiol C Toxicol Pharmacol. 163:64–76. 2014. View Article : Google Scholar : PubMed/NCBI
4	Xu JQ, Liu P, Si MJ and Ding XY: MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol. 34:3871–3877. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bago-Horvath Z, Schmid K, Rössler F, Nagy-Bojarszky K, Funovics P and Sulzbacher I: Impact of RANK signalling on survival and chemotherapy response in osteosarcoma. Pathology. 46:411–415. 2014. View Article : Google Scholar : PubMed/NCBI
6	Guma SR, Lee DA, Ling Y, Gordon N and Kleinerman ES: Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer. 61:1362–1368. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ohba T, Cole HA, Cates JM, Slosky DA, Haro H, Ando T, Schwartz HS and Schoenecker JG: Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J Bone Miner Res. 29:1431–1445. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rabinowicz R, Barchana M, Liphshiz I, Futerman B, Linn S and Weyl-Ben-Arush M: Cancer incidence and survival among children and adolescents in Israel during the years 1998 to 2007. J Pediatr Hematol Oncol. 34:421–429. 2012. View Article : Google Scholar : PubMed/NCBI
9	Salas SI, Jiguet-Jiglaire C, Campion L, Bartoli C, Frassineti F, Deville JL, De Maues Paula A, Forest F, Jézéquel P, Gentet JC and Bouvier C: Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. BMC Cancer. 14:6062014. View Article : Google Scholar : PubMed/NCBI
10	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
11	Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
12	Westlake SLI, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ and Edwards CJ: The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 49:295–307. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun Y, Shen Z, Yao Y and Dong Y: Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 7:270–275. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yang TM, Qi SN, Zhao N, Yang YJ, Yuan HQ, Zhang B and Jin S: Induction of apoptosis through caspase-independent or caspase-9-dependent pathway in mouse and human osteosarcoma cells by a new nitroxyl spin-labeled derivative of podophyllotoxin. Apoptosis. 18:727–738. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ghayad SE and Cohen PA: Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov. 5:29–57. 2010. View Article : Google Scholar : PubMed/NCBI
16	Markman B, Dienstmann R and Tabernero J: Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget. 1:530–543. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C, Mathijssen RH, et al: MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer. 135:348–361. 2014. View Article : Google Scholar : PubMed/NCBI
18	Guled M, Pazzaglia L, Borze I, Mosakhani N, Novello C, Benassi MS and Knuutila S: Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis. Genes Chromosomes Cancer. 53:693–702. 2014. View Article : Google Scholar : PubMed/NCBI
19	Tafra R, Brakus SM, Vukojevic K, Kablar B, Colovic Z and Saraga-Babic M: Interplay of proliferation and proapoptotic and antiapoptotic factors is revealed in the early human inner ear development. Otol Neurotol. 35:695–703. 2014. View Article : Google Scholar : PubMed/NCBI
20	Liu Y, Zhou Y, Feng X, Yang P, Yang J, An P, Wang H, Ye S, Yu C, He Y and Luo H: Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer. 53:358–365. 2014. View Article : Google Scholar : PubMed/NCBI
21	Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
22	Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
23	Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL and Kleinerman ES: Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer. 61:618–626. 2014. View Article : Google Scholar : PubMed/NCBI
24	Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
25	Rainusso N, Brawley VS, Ghazi A, Gottschalk S, Rosen JM and Ahmed N: Immunotherapy targeting HER2 with genetically modified T-cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19:212–217. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ando K, Heymann MF, Stresing V, Mori K, Rédini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI
27	Luckasson R and Schalock RL: What's at stake in the lives of people with intellectual disability? Part II: Recommendations for naming, defining, diagnosing, classifying and planning supports. Intellect Dev Disabil. 51:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
28	Moritake H, Kamimura S, Kojima H, Shimonodan H, Harada M, Sugimoto T, Nao-I N and Nunoi H: Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 60:329–331. 2013. View Article : Google Scholar : PubMed/NCBI
29	Zhang G, Li M, Zhu X and Yang C: Knockdown of Akt sensitizes osteosarcoma cells to apoptosis induced by cisplatin treatment. Int J Mol Sci. 12:2994–3005. 2011. View Article : Google Scholar : PubMed/NCBI
30	Ell B and Kang Y: MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014. View Article : Google Scholar : PubMed/NCBI